Silence Therapeutics (NASDAQ:SLN) Issues Earnings Results

Silence Therapeutics (NASDAQ:SLN) released its quarterly earnings results on Thursday. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.06, FiscalAI reports. Silence Therapeutics had a negative net margin of 254.25% and a negative return on equity of 61.76%. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $2.19 million.

Silence Therapeutics Price Performance

Shares of Silence Therapeutics stock traded down $0.58 during trading on Thursday, reaching $5.20. 166,859 shares of the stock traded hands, compared to its average volume of 252,144. The company has a market capitalization of $245.60 million, a price-to-earnings ratio of -3.85 and a beta of 1.32. The business has a fifty day simple moving average of $5.34 and a two-hundred day simple moving average of $5.75. Silence Therapeutics has a 52-week low of $1.97 and a 52-week high of $7.78.

Analyst Ratings Changes

SLN has been the topic of a number of recent research reports. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a report on Monday. Wall Street Zen upgraded Silence Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $34.50.

Institutional Trading of Silence Therapeutics

A number of large investors have recently made changes to their positions in the business. Millennium Management LLC increased its stake in Silence Therapeutics by 50.3% during the third quarter. Millennium Management LLC now owns 298,512 shares of the company’s stock worth $1,549,000 after acquiring an additional 99,865 shares during the last quarter. Boothbay Fund Management LLC lifted its holdings in shares of Silence Therapeutics by 1.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock worth $1,464,000 after acquiring an additional 2,409 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of Silence Therapeutics by 4.4% during the 4th quarter. Bank of Montreal Can now owns 160,474 shares of the company’s stock worth $976,000 after purchasing an additional 6,692 shares during the period. Marshall Wace LLP grew its holdings in Silence Therapeutics by 87.1% during the 4th quarter. Marshall Wace LLP now owns 155,680 shares of the company’s stock valued at $947,000 after purchasing an additional 72,461 shares during the last quarter. Finally, Opaleye Management Inc. purchased a new stake in Silence Therapeutics in the 4th quarter worth about $480,000. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.